Apixaban FDA Approval for Clotting in Post Orthopedic Surgery Patients

Apixaban FDA Approval for Clotting in Post Orthopedic Surgery Patients

Apixaban CAS 503612-47-3 FDA ApprovedThe FDA offered a nod of approval for the use of Apixaban when treating patients post orthopedic surgery. This recent endorsement of Bristol Myers’ brand name drug Eliquis {Apixaban} is timely and encouraging, with a little over one million orthopedic surgeries performed in the U.S. each year. The high risk of deep vein thrombosis or DVT is a major concern for this patient population, as this dangerous condition often leads to blood clots and fatal pulmonary embolisms. Predicted to be a blockbuster drug on Wall Street last year, Eliquis {Apixaban} has been inching it’s way to several billion dollars in sales over the past twelve months. The Apixaban FDA Approval is likely to boost sales of this wonder drug even father.

Roughly 332,000 patients undergo a hip replacement each in in the United States, and a whopping 719,000 people have knee replacements in the U.S. as well. These patients will be reassured by the FDA’s latest approval of Apixaban as their risk of blood clots in the knees, legs, lungs and hips will be significantly reduced through post-surgical treatment with this anticoagulant. The ease of administration and safety and tolerability record makes Apixaban an ideal treatment for the majority of orthopedic surgery candidates after their procedure. Studies of Apixaban have proven the efficacy of this drug for reducing stroke risks better than the comparator drug warfarin. Additionally, Apixaban has demonstrated a benefit of reducing excessive bleeding, which is a common concern for patients taking anticoagulants medications. This risk reduction has led to improvements in mortality and overall well-being of patients who have received Apixaban after surgical interventions. Practitioners and patients are reassured by Apixaban as it not only works by preventing life threatening blood clots, but it also elicits fewer complications from bleeding incidents. Apixaban is easy to use and does not require regular blood tests and monitoring like its competitor warfarin, which lends this blood thinner to be a medication patients are more likely to adhere to.

LGM Pharma provides the antithrombotic Apixaban CAS# 503612-47-3 API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service